ArticleFrontiers in medicine2022

Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy.

Akihito Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.